{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:47:03Z","timestamp":1789415223277,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Shanghai Cancer Hospital, Fudan University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pegylated liposomal doxorubicin (PLD) was shown to have comparable efficacy to doxorubicin, with significantly reduced cardiotoxicity. This study evaluated the cardiotoxicity and efficacy of the PLD-based regimen compared with those of the doxorubicin-based regimen as adjuvant therapy for early-stage breast cancer (BC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label, randomized controlled trial, patients with early-stage BC were assigned to receive either 4 cycles of PLD (study group) or doxorubicin (control group) plus cyclophosphamide followed by 4 cycles of docetaxel\/paclitaxel. The primary endpoint was cardiotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between November 2017 and September 2019, 247 patients (study group, n\u2005=\u2005131; control group, n\u2005=\u2005116) were enrolled. Incidence rates of abnormal left ventricular ejection fraction (LVEF, 0 vs. 1.7%) and congestive heart failure (0.0% vs. 0.9%) were similar between the two groups (all P\u2005&amp;gt;\u20050.05). A lower proportion of elevated high-sensitivity cardiac troponin T (3.8% vs. 30.2%, P\u2005&amp;lt;\u20050.001) was observed in the study group. The 5-year disease-free survival (82.7% vs. 83.8%) and overall survival (90.4% vs. 91.6%) rates were comparable (all P\u2005&amp;gt;\u20050.05). Grade 3-4 adverse events in the study group were significantly less than in the control group (43.5% vs. 61.2%, P\u2005=\u20050.005).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The PLD-based regimen for early-stage BC showed significantly lower rates of elevated hs-cTnT and grade 3-4 AEs with comparable efficacy to the doxorubicin-based regimen. (ClinicalTrials.gov Identifier: NCT03949634; IRB Approved: Ethics committee institutional review board of Shanghai Cancer Hospital, Fudan University\u2019s (No. 1706173-19-1904B) and other center).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf101","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:41:58Z","timestamp":1744357318000},"source":"Crossref","is-referenced-by-count":10,"title":["Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial"],"prefix":"10.1093","volume":"30","author":[{"given":"Lichen","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai , Shanghai ,","place":["People\u2019s Republic of China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"He","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai , Shanghai ,","place":["People\u2019s Republic of China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuizhi","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Breast Center, the Fourth Hospital of Hebei Medical University , Shijiazhuang ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Bethune First Hospital of Jilin University , Changchun ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast surgery, Xijing Hospital of Air Force Military Medical University , Xi\u2019an ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5298-3411","authenticated-orcid":false,"given":"Guangdong","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Yantai Yuhuangding Hospital , Yantai ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Breast Medicine, Harbin Medical University Cancer Hospital , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Breast Center, West China Hospital of Sichuan University , Chengdu ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Hospital of China Medical University , Shenyang ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[{"name":"Breast Disease Diagnosis and Treatment Center, The Affiliated Hospital of Qingdao University , Qingdao ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Breast Disease Prevention and Treatment Center, Guangdong Women and Children Hospital , Guangzhou ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital, Fudan University , Shanghai ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Zeng","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, Chongqing University Cancer Hospital , Chongqing ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Medicine, Cancer Hospital of The University of Chinese Academy of Sciences Zhejiang Cancer Hospital , Hangzhou ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Breast Surgery, The Central Hospital of Wuhan , Wuhan ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8792-3753","authenticated-orcid":false,"given":"Zhonghua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai , Shanghai ,","place":["People\u2019s Republic of China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai , Shanghai ,","place":["People\u2019s Republic of China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"2025061210283015700_CIT0001","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","article-title":"Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system","volume":"25","author":"Hudis","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025061210283015700_CIT0002","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10549-006-9413-7","article-title":"Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer","volume":"104","author":"Abu-Khalaf","year":"2007","journal-title":"Breast Cancer Res Treat."},{"key":"2025061210283015700_CIT0003","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol."},{"key":"2025061210283015700_CIT0004","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet."},{"key":"2025061210283015700_CIT0005","doi-asserted-by":"publisher","first-page":"18135","DOI":"10.1038\/s41598-019-54387-5","article-title":"Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052)","volume":"9","author":"Li","year":"2019","journal-title":"Sci Rep."},{"key":"2025061210283015700_CIT0006","doi-asserted-by":"publisher","first-page":"645026","DOI":"10.3389\/fonc.2021.645026","article-title":"Long-term cardiac safety and survival outcomes of neoadjuvant pegylated liposomal doxorubicin in elderly patients or prone to cardiotoxicity and triple negative breast cancer. final results of the multicentre phase II CAPRICE study","volume":"11","author":"Gil-Gil","year":"2021","journal-title":"Front Oncol."},{"key":"2025061210283015700_CIT0007","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/annonc\/mdr519","article-title":"Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial","volume":"23","author":"Rayson","year":"2012","journal-title":"Ann Oncol."},{"key":"2025061210283015700_CIT0008","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1186\/s12885-021-09050-6","article-title":"Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Cancer"},{"key":"2025061210283015700_CIT0009","first-page":"159","article-title":"Pegylated liposomal doxorubicin as adjuvant therapy for stage I-III operable breast cancer","volume":"30","author":"Lu","year":"2016","journal-title":"In Vivo"},{"key":"2025061210283015700_CIT0010","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/ajco.12771","article-title":"Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study","volume":"14","author":"Yang","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025061210283015700_CIT0011","first-page":"7319","article-title":"Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer","volume":"34","author":"Lien","year":"2014","journal-title":"Anticancer Res."},{"key":"2025061210283015700_CIT0012","doi-asserted-by":"publisher","first-page":"746114","DOI":"10.3389\/fgene.2021.746114","article-title":"Pegylated liposomal doxorubicin versus epirubicin as adjuvant therapy for stage I-III breast cancer","volume":"12","author":"Hu","year":"2021","journal-title":"Front Genet."},{"key":"2025061210283015700_CIT0013","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.3390\/curroncol28060433","article-title":"Pegylated liposomal doxorubicin (Caelyx(\u00ae)) as adjuvant treatment in early-stage luminal B-like breast cancer: a feasibility phase II trial","volume":"28","author":"Dellapasqua","year":"2021","journal-title":"Curr Oncol"},{"key":"2025061210283015700_CIT0014","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1634\/theoncologist.2017-0672","article-title":"Adjuvant anthracyclines in breast cancer: what is their role","volume":"23","author":"Shah","year":"2018","journal-title":"Oncologist."},{"key":"2025061210283015700_CIT0015","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s00520-015-3008-y","article-title":"Risk factors for anthracycline-associated cardiotoxicity","volume":"24","author":"Reinbolt","year":"2016","journal-title":"Support Care Cancer."},{"key":"2025061210283015700_CIT0016","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/annonc\/mdx773","article-title":"Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study","volume":"29","author":"Swain","year":"2018","journal-title":"Ann Oncol."},{"key":"2025061210283015700_CIT0017","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet."},{"key":"2025061210283015700_CIT0018","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/03008916211067568","article-title":"Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial","volume":"109","author":"Conte","year":"2023","journal-title":"Tumori."},{"key":"2025061210283015700_CIT0019","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.1200\/JCO.2009.23.0946","article-title":"Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial","volume":"27","author":"Spielmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"2025061210283015700_CIT0020","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/aje\/kwz123","article-title":"Cancer survivorship and subclinical myocardial damage","volume":"191","author":"Coughlin","year":"2022","journal-title":"Am J Epidemiol."},{"key":"2025061210283015700_CIT0021","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1002\/ehf2.14373","article-title":"Early diagnostic value of high-sensitivity cardiac troponin T for cancer treatment-related cardiac dysfunction: a meta-analysis","volume":"10","author":"Lv","year":"2023","journal-title":"ESC Heart Failure"},{"key":"2025061210283015700_CIT0022","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"2025061210283015700_CIT0023","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10549-015-3415-2","article-title":"Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study","volume":"151","author":"Gil-Gil","year":"2015","journal-title":"Breast Cancer Res Treat."},{"key":"2025061210283015700_CIT0024","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/cncr.30421","article-title":"Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study","volume":"123","author":"Watanabe","year":"2017","journal-title":"Cancer."},{"key":"2025061210283015700_CIT0025","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/annonc\/mdw098","article-title":"Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial","volume":"27","author":"Mackey","year":"2016","journal-title":"Ann Oncol."},{"key":"2025061210283015700_CIT0026","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/1120009X.2020.1746886","article-title":"Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer","volume":"32","author":"Yao","year":"2020","journal-title":"J Chemother."},{"key":"2025061210283015700_CIT0027","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3760\/cma.j.cn112152-20200410-00330","article-title":"Breast Cancer Group, Chinese Association for Clinical Oncologist (CACO). [Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)]","volume":"42","author":"Yuan","year":"2020","journal-title":"Zhonghua Zhong Liu Za Zhi [Chin J Oncol]."},{"key":"2025061210283015700_CIT0028","doi-asserted-by":"publisher","first-page":"909426","DOI":"10.3389\/fonc.2022.909426","article-title":"Pegylated liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant treatment for HER2-positive breast cancer patients: a phase II and biomarker study","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol."},{"key":"2025061210283015700_CIT0029","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/oncolo\/oyad160","article-title":"A phase II study of neoadjuvant PLD\/cyclophosphamide and sequential nab-Paclitaxel Plus Dual HER2 blockade in HER2-positive breast cancer","volume":"29","author":"Yang","year":"2023","journal-title":"Oncologist."},{"key":"2025061210283015700_CIT0030","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"2025061210283015700_CIT0031","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S1470-2045(13)70567-9","article-title":"Breast cancer in China","volume":"15","author":"Fan","year":"2014","journal-title":"Lancet Oncol."},{"key":"2025061210283015700_CIT0032","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","article-title":"Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28","volume":"23","author":"Mamounas","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025061210283015700_CIT0033","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer","volume":"24","author":"Jones","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf101\/63478025\/oyaf101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf101\/63478025\/oyaf101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T10:28:43Z","timestamp":1749724123000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf101\/8160963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf101","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"oyaf101"}}